Print Page | Sign In | Join Today
Medicare
Share |

Virginia Bio opposes a cut to Medicare Part B, as such a cut will limit healthcare access for the most vulnerable patients in our population.

Medicare Part B coverage of drugs provides an invaluable route of access for patients facing chronic illness. Part B provides an important pathway for patients to access a narrowly defined, limited number of provider-administered products (e.g., those that are injected or infused under the direction of a physician). Furthermore, the patients served under Part B are often the sickest and, therefore, most vulnerable.

When you communicate with your Members of Congress, please indicate your support for maintaining Medicare Part B as is. It is always vulnerable, and a perennial concern.

View Medicare Part B Primer

Virginia Bio opposes government intervention in the price structure associated with Medicare Part D benefits.

Proposals to enable the federal government to directly intervene in drug supply and cost negotiations could negatively affect the prices paid for prescription drugs, distort the competitive dynamic of the program and result in a range of unintended consequences, including a significant increase in beneficiary premiums, a negative impact on innovation, and cost-shifting to other consumers.

While no specific legislation is yet pending to interfere with the successful negotiation mechanism now in place for Medicare Part D, there is increasingly a call by opponents to do so, and it is likely soon to be a contested issue.

When you communicate with your Members of Congress, please indicate your support for maintaining Medicare Part D as is.

View Medicare Part D Primer

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected